These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 26878692)

  • 21. Advances in pharmacotherapy of small cell lung cancer.
    Kalemkerian GP
    Expert Opin Pharmacother; 2014 Nov; 15(16):2385-96. PubMed ID: 25255939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical treatment of small cell lung cancer: state of the art and new development.
    Sgambato A; Casaluce F; Maione P; Rossi A; Sacco PC; Panzone F; Ciardiello F; Gridelli C
    Expert Opin Pharmacother; 2013 Oct; 14(15):2019-31. PubMed ID: 23901936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
    Imai H; Sugiyama T; Tamura T; Minemura H; Kaira K; Kanazawa K; Yokouchi H; Kasai T; Kaburagi T; Minato K;
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):615-622. PubMed ID: 28761968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcome of amrubicin therapy according to the prior chemotherapy sensitivities of extensive small cell lung cancer.
    Mitsuoka S; Kudoh S; Kimura T; Yoshimura N; Tanaka H; Suzumura T; Umekawa K; Nagata M; Ueda T; Hirata K
    Osaka City Med J; 2011 Dec; 57(2):59-66. PubMed ID: 22443079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
    Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
    J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New advances in the second-line treatment of small cell lung cancer.
    Hurwitz JL; McCoy F; Scullin P; Fennell DA
    Oncologist; 2009 Oct; 14(10):986-94. PubMed ID: 19819917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion.
    Das M; Padda SK; Weiss J; Owonikoko TK
    Adv Ther; 2021 Nov; 38(11):5431-5451. PubMed ID: 34564806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topotecan in the treatment of recurrent small cell lung cancer: an update.
    Ardizzoni A
    Oncologist; 2004; 9 Suppl 6():4-13. PubMed ID: 15616145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401.
    Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M
    Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.
    Chiappori AA; Otterson GA; Dowlati A; Traynor AM; Horn L; Owonikoko TK; Ross HJ; Hann CL; Abu Hejleh T; Nieva J; Zhao X; Schell M; Sullivan DM
    Oncologist; 2016 Oct; 21(10):1163-1164. PubMed ID: 27694157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current Diagnosis and Management of Small-Cell Lung Cancer.
    Wang S; Zimmermann S; Parikh K; Mansfield AS; Adjei AA
    Mayo Clin Proc; 2019 Aug; 94(8):1599-1622. PubMed ID: 31378235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancer.
    Igawa S; Otani S; Ryuge S; Fukui T; Nakahara Y; Hiyoshi Y; Ishihara M; Kusuhara S; Harada S; Mitsufuji H; Kubota M; Sasaki J; Masuda N
    Invest New Drugs; 2017 Oct; 35(5):642-648. PubMed ID: 28631097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation.
    Hartwell D; Jones J; Loveman E; Harris P; Clegg A; Bird A
    Cancer Treat Rev; 2011 May; 37(3):242-9. PubMed ID: 20709456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of topotecan as second-line chemotherapy for small cell lung cancer patients with interstitial lung disease.
    Suzuki H; Hirashima T; Kobayashi M; Sasada S; Okamoto N; Uehara N; Matsuura Y; Tamiya M; Morishita N; Higashiguchi M; Tsumori T; Kawase I
    J Chemother; 2011 Dec; 23(6):367-70. PubMed ID: 22233823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging drugs for small cell lung cancer: a focused review on immune checkpoint inhibitors.
    Reddy HG; Qin A; Kalemkerian GP
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):353-366. PubMed ID: 32683991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of topotecan as a second line treatment in small cell lung cancer patients. Preliminary report].
    Biernacka B; Krawczyk P; Buczkowski J; Siwiec A; Perzyło K; Milanowski J
    Pneumonol Alergol Pol; 2010; 78(3):192-202. PubMed ID: 20461687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy.
    Scagliotti G; Nishio M; Satouchi M; Valmadre G; Niho S; Galetta D; Cortinovis D; Benedetti F; Yoshihara E; Makris L; Inoue A; Kubota K
    Lung Cancer; 2016 Oct; 100():20-23. PubMed ID: 27597276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis.
    Genestreti G; Tiseo M; Kenmotsu H; Kazushige W; Di Battista M; Cavallo G; Carloni F; Bongiovanni A; Burgio MA; Casanova C; Metro G; Scarpi E; Korkmaz T; Selcuk S; Roopa K; Califano R
    Clin Lung Cancer; 2015 Nov; 16(6):e223-8. PubMed ID: 25983005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy for small-cell lung cancer: emerging evidence.
    Reck M; Heigener D; Reinmuth N
    Future Oncol; 2016 Apr; 12(7):931-43. PubMed ID: 26882955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.